After comparing the HRs for BCSS and DFS in all subgroups using a multivariate analysis during a 5- and 10-year follow-up, our results suggested that higher ER or PgR expression level was associated with better 5-year BCSS and DFS among breast cancer patients received adjuvant hormone therapy. The gene discussed is ESR1; the disease is breast carcinoma.